Most People Mount a Strong Antibody Response to SARS-CoV-2 That Does Not Decline Rapidly

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

Read more

Mount Sinai Selected to Serve as Capacity Building Center and Center of Excellence as Part of the National Cancer Institute’s New Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute (NCI) as part of the NCI’s new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19. Mount Sinai was selected as one of only four Capacity Building Centers and one of eight Centers of Excellence as part of this new network.

Read more

New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test

The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood

Read more

Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19

If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.

Read more